Aurobindo Pharma (AUROPHARMA.NS) Stock Price
Aurobindo Pharma Price
Revenue has compounded at 15.7% per year over the past 19 years to 336.53 B INR. Earnings per share have grown at 16.2% per year over the last 19 years. Aurobindo Pharma's net margin stands at 10.4%, broadly stable from 11.3% several years earlier. Aurobindo Pharma currently offers a dividend yield of about 0.24%. The payout ratio is around 9% of earnings. The dividend has grown at 15.7% per year over the past 19 years. Analysts set a median price target of 1,407.60 INR, implying 17.0% below the current price. Of 31 analysts, 25 rate the stock a buy — an overall Buy consensus.
Aurobindo Pharma stock price
Aurobindo Pharma business model & stock analysis
Frequently asked questions about Aurobindo Pharma
Aurobindo Pharma Ltd is a pharmaceutical company that operates under a vertically integrated business model. The company is engaged in the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs) globally. With a strong focus on research and development, Aurobindo Pharma strives to provide affordable and high-quality healthcare products to patients worldwide. The company's diverse product portfolio spans multiple therapeutic areas, including antiretrovirals, antibiotics, cardiovasculars, and more. Aurobindo Pharma's commitment to innovation, quality, and accessibility has catapulted it to become one of the leading players in the generic pharmaceutical industry.
Aurobindo Pharma Ltd primarily operates in the pharmaceutical industry.
Some of the main competitors of Aurobindo Pharma Ltd in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma Ltd is a leading pharmaceutical company with a rich history and background. Established in 1986, the company has rapidly grown to become one of the largest vertically integrated generic pharmaceutical companies globally. Headquartered in Hyderabad, India, Aurobindo Pharma is committed to delivering high-quality, affordable medicines across various therapeutic areas. With a strong focus on research and development, the company has a diverse portfolio of over 400 products approved by regulatory authorities in more than 150 countries. Aurobindo Pharma's consistent growth and dedication to healthcare have earned it a strong reputation in the pharmaceutical industry.
Aurobindo Pharma Ltd has accomplished several significant milestones in its journey. By adhering to high-quality standards and manufacturing innovative pharmaceutical products, the company has gained recognition worldwide. Aurobindo Pharma Ltd has achieved notable milestones such as receiving the US FDA approval for multiple abbreviated new drug applications (ANDAs), expanding its global footprint through strategic acquisitions, and consistently delivering strong financial performance. With a focus on research and development, Aurobindo Pharma Ltd continues to enhance its product portfolio and bring affordable healthcare solutions to patients across the globe.
Aurobindo Pharma Ltd is primarily present in various countries and regions across the globe. The company has a strong global footprint and operates in over 150 countries, including key markets such as the United States, Europe, India, and several other emerging markets. Aurobindo Pharma Ltd has established a significant presence in these regions, leveraging its robust manufacturing capabilities, research and development expertise, and a wide range of high-quality generic pharmaceutical products. The company's extensive international presence enables it to cater to a diverse customer base and contribute to improving healthcare access worldwide.
Aurobindo Pharma Ltd represents values of excellence, integrity, and innovation. The company's corporate philosophy revolves around delivering high-quality and affordable pharmaceutical products to improve global healthcare. Aurobindo Pharma is committed to maintaining the highest standards of regulatory compliance and ensuring patient safety. With a focus on research and development, the company strives to create and provide access to a diverse range of medicines across various therapeutic areas. Aurobindo Pharma's mission is to enhance the well-being and quality of life for individuals worldwide by consistently delivering superior value to its stakeholders in an ethical and sustainable manner.
Analysts currently set an average price target of 1,374.72 INR for the Aurobindo Pharma stock (median: 1,407.60 INR), implying -18.9 % versus the latest price. The consensus is based on 31 analyst ratings.
32 analysts currently rate the Aurobindo Pharma stock: 26 recommend buying, 1 holding and 5 selling.
Converted at the current exchange rate, the Aurobindo Pharma share trades at 15.86 EUR (1,695.70 INR).
The Aurobindo Pharma share (AUROPHARMA.NS) is listed on 2 stock exchanges, including: NSE (Indien) (AUROPHARMA.NS).
Aurobindo Pharma Ltd is a leading global pharmaceutical manufacturer with a wide portfolio of pharmaceuticals and active pharmaceutical ingredients (APIs). The company is headquartered in India and operates 18 production facilities in 7 countries worldwide to serve a variety of therapy areas such as oncology, neurology, anti-infectives, and cardiology. Aurobindo Pharma Ltd has a well-diversified business with various segments focusing on the manufacturing and marketing of pharmaceutical formulations and APIs for the domestic and international markets. The focus is on developing high-quality and cost-effective products to meet the needs of patients worldwide. One of the key segments of Aurobindo Pharma Ltd is generic manufacturing. The company produces a variety of generics for use in various therapy areas such as pain relief, diabetes, cardiovascular diseases, and infectious diseases. Additionally, the company also offers customized development services for companies in need of new formulations and APIs. Another important segment of Aurobindo Pharma Ltd is API production. The company produces a wide range of APIs used in the manufacturing of generics and finished pharmaceuticals. The focus is on manufacturing products of the highest quality at a competitive price. Aurobindo Pharma Ltd is also a leading provider of in vitro diagnostics and diabetology products. The company also offers biological products and biosimilars. Aurobindo Pharma Ltd strives to bring innovative biological drugs to the market that contribute to improving health and quality of life. The focus is on developing biosimilars that are cost-effective while meeting the highest standards of quality and safety. The company also has a presence in the field of new molecule development. Aurobindo Pharma Ltd, as well as its subsidiaries Agila Specialties and Oncobiologics, focus on the development and marketing of proprietary products that contribute to patient care improvement. In summary, Aurobindo Pharma Ltd has broad business activities, including the manufacturing and marketing of pharmaceutical formulations, APIs, and biological products. The company's focus is on offering cost-effective, high-quality products to enhance healthcare worldwide. Aurobindo Pharma Ltd is a leading provider of generics and also offers customized development and production services. The company will continue to invest in the development of new molecules to further diversify its portfolio.
The revenue of Aurobindo Pharma is 336.53 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Aurobindo Pharma is 35.05 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Aurobindo Pharma is currently 27.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Aurobindo Pharma stock.
The price-to-sales ratio (P/S) of Aurobindo Pharma is currently 2.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Aurobindo Pharma stock.
The Eulerpool Quality Score for Aurobindo Pharma is 5/10.
The ISIN of Aurobindo Pharma is INE406A01037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Aurobindo Pharma is AUROPHARMA.NS. The ticker symbol is used to trade Aurobindo Pharma shares on the stock exchange.
Aurobindo Pharma stock
Aurobindo Pharma Peer Group
Aurobindo Pharma Ticker
Aurobindo Pharma FIGI
All fundamentals and in-depth analysis of Aurobindo Pharma
Our stock analysis for Aurobindo Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurobindo Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.